Short description
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Description
Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio.
Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Hayward, California, United States, North America
Founded on
January 1, 2015
Exited on
March 14, 2018
Went public on
March 14, 2018
Stock symbol
RCUS
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$34056 - 789030
Sign in for full access
Investors
No Way, No Way, Noaccessforu, Absolutely Noaccess, Absolutely Noaccess, Noaccess, Noaccessforu, Blurry Noaccess, Nopepepe, Noway Youcantaccess, Nopepepe, Cannot Access, Noaccessforu, Nopepepe, Absolutely Noaccess, Cannot Access, Noaccessforu, Nopepepe
Sign in for full access
Founders
Juan Jaen, Terry Rosen